A global biopharma focused on severe diseases with operations in approximately 40 countries and global revenue of € 3.3 billion in 2014. We combine biology and chemistry to make major breakthroughs. By integrating our expertise in large, antibody-based molecules and small, c...
Keine Kommentare verfügbar.
Bewertung & Kommentar hinterlassen